Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,570.29
(
-0.82%
)
US TECH 100
23,594.80
(
-0.85%
)
Dow Jones
45,797.81
(
-0.92%
)
Brent Oil
105.95
(
-0.60%
)
Bitcoin
69,576.49
(
-2.34%
)
News Focus
News Focus
Post# of 257259
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122799
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: p3analyze post# 87439

Wednesday, 12/16/2009 9:41:40 PM

Wednesday, December 16, 2009 9:41:40 PM

Post# of 257259
ODAC votes 12-1 against Tarceva in NSCLC maintenance therapy:

http://finance.yahoo.com/news/FDA-Advisory-Committee-bw-432658505.html?x=0&.v=1

Although the study in question showed a statsig benefit in both PFS and OS for Tarceva vs placebo following first-line platinum chemo, panel members were unimpressed by the clinical significance of these improvements. LLY’s Alimta is approved in this maintenance setting.

OSIP is holding a CC Thursday at 8:30am ET.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now